Spring direct naar de hoofdnavigatie of de inhoud
‘To explore, together with a client, how the best IP protection can be obtained is for me the logical next step after an invention has been made.’
Frits Michiels

Frits Michiels

  • Life Sciences
  • European and Dutch Patent Attorney
  • Valuation specialist
  • Partner

Frits Michiels has had an extensive scientific career in both knowledge institutes and biotech companies. From 2004, he was employed as IP manager at Galapagos Genomics BV and subsequently also at other Dutch biotech startups, such as Agendia and Merus. He has worked for V.O. since 2006.

Continue reading

He is specialized in biochemistry, molecular biology, cell biology, diagnostics, signal transduction, and medical biotechnology. His clients are primarily knowledge institutes and start ups. He is involved in patent prosecution and strategic advice.

Working experience

  • Patent Attorney, V.O. (2006-present)
  • Merus (2006)
  • Galapagos Genomics (1999-2005)
  • Senior Scientist at the Netherlands Cancer Institute (1994-1998)
  • Post-Doc, Amsterdam Medical Center (1991-1993)
  • PhD research at Max Planck Institute for Biochemistry, Munich (1985-1990)

Education

  • PhD in Genetics, Radboud University Nijmegen (1990)
  • MSc in Microbiology, Radboud University Nijmegen (1984)

Publications

  • Michiels, GAM Damages extended to after termination of a tort. MIP Vol 205: 94-95 (2011)
  • JP ten Klooster, EE Evers, L Janssen, LM Machesky, F Michiels, P Hordijk and JG Collard. Biochem J. 397, 39–45 (2006)
  • GJ Arts, E Langemeijer, R Tissingh, L Ma, H Pavliska, K Dokic, R Dooijes, E Mesić, R Clasen, F Michiels, J van der Schueren, M Lambrecht, S Herman, R Brys, K Thys, M Hoffmann, P Tomme, H van Es. Genome Res 13, 2325-32 (2003)
  • A Malliri, RA van der Kammen, K Clark, M van der Valk, F Michiels & JG Collard. Nature 417, 867-871 (2002)
  • F Michiels et al. Nature Biotech 20, 1154-1157 (2002)
  • R Engers, E Springer, F Michiels, JG Collard, HE Gabbert. J Biol Chem 276, 41889-97 (2001)
  • WO2002057463 Swap/counter selection; a rapid cloning
  • WO2002070744 Adenoviral library assay for E2F regulatory genes and methods and compositions for screening compounds method
  • WO2005124342 Methods and means for treatment of osteoarthritis

Languages

  • English
  • Dutch
  • German

Also see these experts

Annemiek Tepper

Annemiek Tepper

  • European and Dutch Patent Attorney, European Patent Litigator
  • Partner
Mark Einerhand

Mark Einerhand

  • European and Dutch Patent Attorney
  • Partner
More experts

News

What about your ‘T & C’?

The importance of terms and conditions is often underestimated – writing the two words in full is sometimes even too much. “Who reads them at all?”, ‘We don’t even know what’s in them ourselves’, ‘We rarely fall back on them’ and ‘Why would we want to put general terms and conditions forward if the cooperation […]Continue reading

Upcoming decision on legal criterion for ‘novelty’

One of the most important requirements for obtaining a patent on a product in Europe is that the product is novel. That means that before the day on which the patent application was filed, the product was not yet available to the public in any way.Continue reading

An update on the unitary patent system

As of 1 June 2023, the European Patent Office (EPO) offers the possibility to register a granted European patent as a unitary patent. This unitary patent has effect in 18 European Union (EU) member states, representing 80% of the GDP of the EU. Before its start, it was uncertain if patentees would readily embrace the […]Continue reading

Events

Beta Business Days 2025

Martiniplaza, Leonard Springerlaan, Groningen, Netherlands

The Beta Business Days is a two-day event aimed at establishing contacts between companies and ambitious students from Groningen.

Continue reading